Intelligencia AI

📍 New York, United States🗓 Founded 2017👥 132 employees💰 Last funded Aug 2021
Software Development🌐 intelligencia.ai
Website LinkedIn
Intelligencia uses Artificial Intelligence to de-risk drug development. Our platform focuses on estimating the risk of clinical trials, and interpreting the multitude of factors that contribute to that risk. We therefore aim to bridge the gap between innovation and risk reduction, with the ultimate goal of bringing novel therapies to patients faster. Our interdisciplinary team of software engineers, AI practitioners, scientists, and drug developers brings together and interprets disparate data across the life sciences industry. Our platform offers a suite of functionalities that provide unprecedented data clarity and Machine-Learning fueled predictions to enable critical decision making. We currently work with several of the largest global pharmaceutical companies and mid-size and smaller biotechnology companies. Diseases will impact nearly every individual. At Intelligencia AI, we work to make a difference.
1
Total investors
0
Early stage
1
Mid stage
0
Late stage
2017
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Intelligencia AI?
Intelligencia AI has 1 investors on record on gritt.io, 1 mid-stage.
When did Intelligencia AI last raise funding?
The most recent investment in Intelligencia AI recorded on gritt.io was in August 2021.
When was Intelligencia AI founded?
Intelligencia AI was founded in 2017.
What industry is Intelligencia AI in?
Intelligencia AI operates in Software Development. Find similar Software Development investors on gritt.io.
Where is Intelligencia AI based?
Intelligencia AI is headquartered in New York, United States.